News
Author: admin als-handoff
-
Achieve Life Sciences Awarded Grant from the National Institutes of Health to Conduct Phase 2 Trial of Cytisinicline in Nicotine e-cigarette Users
Company awarded $2.5 million to enable initiation of the Phase 2 ORCA-V1 clinical trial. SEATTLE and VANCOUVER, British Columbia, June 1, 2022 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it…
-
Achieve Life Sciences Announces Participation at LD Micro Invitational Conference
SEATTLE, Wash. and VANCOUVER, British Columbia, May 26, 2022 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it will be participating at the LD Micro Invitational Conference. The Conference is taking place in-person at the…
-
Achieve Life Sciences Announces Participation at Best Ideas Virtual Investor Conference
SEATTLE, Wash. And VANCOUVER, British Columbia, May 13, 2022 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it will be participating at the Spring Into Action Best Ideas Virtual Investor Conference. The conference is taking…
-
Achieve Reports Financial Results for First Quarter 2022 and Provides Corporate Update
Company to host conference call at 4:30 PM EDT today, May 12, 2022. SEATTLE, Wash and VANCOUVER, British Columbia, May 12, 2022 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced first quarter 2022 financial results…
-
Achieve Life Sciences Announces Successful, Statistically Significant Smoking Cessation Results in Phase 3 ORCA-2 Clinical Trial of Cytisinicline in Adult Smokers
Clinically robust and statistically significant results in primary and secondary endpoints for both 6- and 12-week cytisinicline treatment compared to placebo. Primary endpoints demonstrated 6-8x increased odds of smoking abstinence with cytisinicline compared to placebo. Cytisinicline was well tolerated with single-digit rates of adverse events observed. Management to host conference call today, April 27th at…